Growth Metrics

Standard Biotools (LAB) Divestments (2020 - 2026)

Standard Biotools (LAB) reported Divestments of $363.2 million for Q1 2026, up 18061.1% on a QoQ basis from $2.0 million in Q3 2021.

Standard Biotools (LAB) has 3 years of Divestments data on file, last reported at $363.2 million in Q1 2026.

  • Quarterly Divestments changed N/A year-over-year to $363.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363.2 million (changed N/A YoY) and the FY2021 annual result came in at $1.3 million, down 93.73% from the prior year.
  • Divestments rose to $363.2 million in Q1 2026 per LAB's latest filing, from $2.0 million in the prior quarter.
  • Across five years, Divestments topped out at $363.2 million in Q1 2026 and bottomed at $363.2 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Divestments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Standard Biotools 448.37 Mn -6.80 Mn 11.31 Mn 363.22 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 363.22 Mn
Sep 30, 2021 2.00 Mn
Jun 30, 2021 2.00 Mn
Mar 31, 2021 2.00 Mn
Dec 31, 2020 9.89 Mn
Sep 30, 2020 11.15 Mn